

HIV-infected adults with a CD4 cell count greater than 500 cells/mm³ on long-term combination antiretroviral therapy reach same mortality rates as the general population.

Charlotte Lewden, Geneviève Chêne, Philippe Morlat, Francois Raffi, Michel Dupon, Pierre Dellamonica, Jean-Luc Pellegrin, Christine Katlama, Francois Dabis, Catherine Leport

► **To cite this version:**

Charlotte Lewden, Geneviève Chêne, Philippe Morlat, Francois Raffi, Michel Dupon, et al.. HIV-infected adults with a CD4 cell count greater than 500 cells/mm³ on long-term combination antiretroviral therapy reach same mortality rates as the general population.. Journal of Acquired Immune Deficiency Syndromes, Lippincott, Williams & Wilkins, 2007, 46 (1), pp.72-7. 10.1097/QAI.0b013e318134257a . inserm-00170726

HAL Id: inserm-00170726

<https://www.hal.inserm.fr/inserm-00170726>

Submitted on 1 Sep 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Table 1. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, overall and according to gender, HIV transmission group and co-infection by hepatitis C virus at baseline.

| | N | Median follow-up (years) | (interquartile range, IQR) | Person-years (PY) | Deaths (n) | Rates (/100 PY) | (95% CI) | SMR | (95% CI) |
|------------------------|------|--------------------------------|-------------------------------|----------------------|---------------|-----------------------|-----------|------|-------------|
| Overall | 2435 | 6.8 | (4.1-7.9) | 13954 | 288 | 2.1 | (1.8-2.3) | 7.0 | (6.2-7.8) |
| Men | 1864 | 6.9 | (4.1-7.9) | 10777 | 226 | 2.1 | (1.8-2.4) | 4.8 | (4.2-5.5) |
| Women | 571 | 6.5 | (3.9-7.8) | 3177 | 62 | 2.0 | (1.5-2.4) | 13.0 | (10.0-16.7) |
| Hepatitis C | | | | | | | | | |
| positive | 574 | 6.4 | (3.6-7.8) | 3163 | 99 | 3.1 | (2.5-3.7) | 13.9 | (11.3-17.0) |
| negative | 1434 | 7.0 | (4.4-7.9) | 8519 | 120 | 1.4 | (1.2-1.7) | 4.4 | (3.6-5.2) |
| HIV transmission group | | | | | | | | | |
| injecting drug users | 527 | 6.2 | (3.2-7.8) | 2849 | 93 | 3.3 | (2.6-3.9) | 16.3 | (13.2-20.0) |
| others | 1908 | 6.9 | (4.2-7.9) | 11104 | 195 | 1.8 | (1.5-2.0) | 5.5 | (4.7-6.3) |

HIV: Human Immunodeficiency Virus; CI: confidence interval

Table 2. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, according to cumulated time spent within each category of CD4 cell count.

| | N patients | Median time spent (years) | (interquartile range, IQR) | Person-years (PY) | Deaths (n) | Rates (/100 PY) | (95% CI) | SMR | (95% CI) |
|--|---------------|---------------------------------|-------------------------------|----------------------|---------------|-----------------------|-----------|------|-------------|
| CD4 cell count $\geq 500/\text{mm}^3$ | 1208 | 4.5 | (2.1-7.0) | 5402 | 37 | 0.7 | (0.5-0.9) | 2.5 | (1.8-3.5) |
| CD4 cell count 350 to 499/ mm^3 | 1263 | 2.0 | (1.0-4.0) | 3446 | 40 | 1.2 | (0.8-1.5) | 3.5 | (2.5-4.8) |
| CD4 cell count 200 to 349/ mm^3 | 1296 | 2.0 | (0.6-3.9) | 3178 | 56 | 1.8 | (1.3-2.2) | 5.6 | (4.2-7.2) |
| CD4 cell count $<200/\text{mm}^3$ | 1118 | 0.6 | (0.2-2.7) | 1928 | 155 | 8.0 | (6.8-9.3) | 30.3 | (25.8-35.5) |

HIV: Human Immunodeficiency Virus; CI: confidence interval

Table 3. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, according to cumulated time spent with CD4 cell count ≥ 500 /mm³, after the time of truncation[§].

| Time of truncation [§] after initiation of cART (year) | Total | | | Patients with CD4 ≥ 500 /mm ³ after the time of truncation | | | | | | | | |
|--|---------------|--------------------------|---------------|--|------------------------------------|-------------------------------|------|---------------|--------------------|-----------|-----|-----------|
| | N patients | Person- years (PY) | Deaths (n) | N patients | Median time spent (years) | (interquartile range, IQR) | PY | Deaths (n) | Rates (/100 PY) | (95% CI) | SMR | (95% CI) |
| 0 | 2435 | 13954 | 288 | 1208 | 4.5 | (2.1-7.0) | 5402 | 37 | 0.7 | (0.5-0.9) | 2.5 | (1.8-3.5) |
| 1 | 2182 | 11685 | 208 | 1156 | 4.2 | (2.1-6.4) | 4817 | 29 | 0.6 | (0.4-0.8) | 2.1 | (1.4-3.1) |
| 2 | 2065 | 9561 | 176 | 1083 | 4.0 | (2.1-5.6) | 4080 | 26 | 0.6 | (0.4-0.9) | 2.2 | (1.4-3.2) |
| 3 | 1949 | 7551 | 141 | 1031 | 3.5 | (1.8-4.8) | 3345 | 22 | 0.7 | (0.4-0.9) | 2.1 | (1.3-3.2) |
| 4 | 1835 | 5660 | 108 | 967 | 3.0 | (1.5-3.8) | 2606 | 18 | 0.7 | (0.4-1.0) | 2.1 | (1.3-3.4) |
| 5 | 1648 | 3915 | 62 | 864 | 2.4 | (1.4-3.0) | 1880 | 12 | 0.6 | (0.3-1.0) | 1.9 | (1.0-3.2) |
| 6 | 1430 | 2389 | 25 | 763 | 1.6 | (1.0-2.2) | 1189 | 2 | 0.2 | (0.0-0.4) | 0.5 | (0.1-1.6) |
| 7 | 1143 | 1084 | 6 | 610 | 0.9 | (0.5-1.3) | 543 | 1 | 0.2 | (0.0-0.5) | 0.5 | (0.0-2.6) |

[§]truncation: the time period taken into account starts 1, 2, 3,... years after initiation of cART

HIV: Human Immunodeficiency Virus; cART: combination antiretroviral therapy; CI: confidence interval

Table 4. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, according to time spent with CD4 cell count between 350 and 499 /mm³, after the time of truncation[§].

| Time of truncation [§] after initiation of cART (year) | Total | | | Patients with CD4 350 to 499 /mm ³ after the time of truncation | | | | | | | | |
|--|------------|-------------------|------------|--|---------------------------|----------------------------|------|------------|-----------------|-----------|-----|-----------|
| | N patients | Person-years (PY) | Deaths (n) | N patients | Median time spent (years) | (interquartile range, IQR) | PY | Deaths (n) | Rates (/100 PY) | (95% CI) | SMR | (95% CI) |
| 0 | 2435 | 13954 | 288 | 1263 | 2.0 | (1.0-4.0) | 3446 | 40 | 1.2 | (0.8-1.5) | 3.5 | (2.5-4.8) |
| 1 | 2182 | 11685 | 208 | 1036 | 2.5 | (1.4-4.0) | 2960 | 35 | 1.2 | (0.8-1.6) | 3.4 | (2.4-4.8) |
| 2 | 2065 | 9561 | 176 | 915 | 2.2 | (1.4-3.7) | 2434 | 29 | 1.2 | (0.8-1.6) | 3.3 | (2.2-4.7) |
| 3 | 1949 | 7551 | 141 | 816 | 2.0 | (1.1-3.4) | 1925 | 26 | 1.4 | (0.8-1.9) | 3.6 | (2.3-5.2) |
| 4 | 1835 | 5660 | 108 | 705 | 1.9 | (1.0-3.0) | 1430 | 20 | 1.4 | (0.8-2.0) | 3.5 | (2.2-5.5) |
| 5 | 1648 | 3915 | 62 | 557 | 1.7 | (0.8-2.7) | 971 | 10 | 1.0 | (0.4-1.7) | 2.5 | (1.2-4.6) |
| 6 | 1430 | 2389 | 25 | 410 | 1.5 | (0.7-2.0) | 572 | 5 | 0.9 | (0.1-1.6) | 2.0 | (0.7-4.8) |
| 7 | 1143 | 1084 | 6 | 286 | 0.8 | (0.5-1.3) | 257 | 2 | 0.8 | (0.0-1.9) | 1.9 | (0.2-6.7) |

[§]truncation: the time period taken into account starts 1, 2, 3,... years after initiation of cART

HIV: Human Immunodeficiency Virus; cART: combination antiretroviral therapy; CI: confidence interval